A Clinical Guide to Inositols
Edited by: Vittorio Unfer and Didier Dewailly
Pubblicato il 20/02/2023
Edited by: Vittorio Unfer and Didier Dewailly
ISBN: 978-0-323-91673-8
Language: English
Published: 2023
Description
A growing body of research demonstrates the potential benefits of the administration of inositol isomers in the treatment of many different disorders, from reproductive to metabolic diseases.
A Clinical Guide to Inositols discusses scientific evidence of inositol-based treatments in different clinical fields to provide clinicians with a practical guide to use inositol supplementation within pathological conditions. Each chapter covers a specific disorder and describes aspects of the application of inositol in clinical practice, discussing the physio-pathologic features of the health condition and scientific evidences of the effects of inositol treatment.This book is a valuable resource to researchers and clinicians looking for a clear understanding of clinical effects of inositol supplementation and a practical guide on inositol-based treatments.
Key Features
• Covers basic knowledge about the biochemistry and physiology of inositol and their pharmacological targets and metabolites
• Discusses scientific evidence of the benefits of inositol supplementation for the clinical management of different diseases
• Addresses inositol application from the gynecological and obstetrical field to, among others, the metabolic, fetal, andrological, endocrine, and oncological fields
Chapter 6 - Myo-inositol could restore peripheral inositol depletion induced by treatments for psychiatric and neurological conditions
Tonino Cantelmi and Cherubino Di Lorenzo
Pages 73-85
Abstract
Neurological and psychiatric conditions, like bipolar disorder (BD), include the excessive activation of neuronal phosphoinositide signaling pathway among the pathogenetic mechanisms. The pharmacological management relies on the use of mood stabilizers like lithium (Li+), valproic acid (VA), and carbamazepine (CBZ) with the aim to reduce the firing and the severity of the manic phases, which are typical of BD. One of their mechanisms of action consists in reducing levels of inositol in the brain, whose high levels in the central nervous system (CNS) correlate with the firing of the manic phases. However, the use of such drugs exposes patients to various side effects that share an altered metabolism of inositols. Indeed, the inositol depletion occurring in CNS as a therapeutic outcome involves also peripheral tissues thus determining the occurrence of pathological conditions like hypothyroidism, polycystic ovary syndrome (PCOS), weight gain, cardiac and renal alterations, dermatological problems. To date, clinicians have no tools to counteract such side effects; therefore, inositol administration represents a step forward in the management of patients with BD bridging the therapeutic gap in clinical practice.